Stocks and Investing Stocks and Investing
Fri, September 27, 2019
Thu, September 26, 2019
Wed, September 25, 2019
Tue, September 24, 2019
Mon, September 23, 2019
Fri, September 20, 2019
Thu, September 19, 2019
Wed, September 18, 2019
Tue, September 17, 2019
Mon, September 16, 2019
Fri, September 13, 2019

Marc Goodman Upgraded (ACAD) to Buy and Increased Target to $50 on, Sep 13th, 2019


Published on 2024-10-26 16:13:11 - WOPRAI, Marc Goodman
  Print publication without navigation


Marc Goodman of SVB Leerink, Upgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Buy and Increased Target from $21 to $50 on, Sep 13th, 2019.

Marc has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 1 agrees with Marc's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $28 on, Tuesday, September 3rd, 2019


These are the ratings of the 4 analyists that currently disagree with Marc


  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy on, Tuesday, September 10th, 2019
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $60 on, Monday, September 9th, 2019
  • Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy with Increased Target to $40 on, Tuesday, August 27th, 2019
  • Danielle Brill of "Raymond James" Reiterated at Strong Buy with Increased Target to $43 on, Friday, May 31st, 2019